Obagi Medical Products, Inc. Launches CLENZIderm M.D. Penetrating Acne Therapeutic System.

New Acne System Clinically Proven to Provide Best-in-Class Efficacy

LONG BEACH, Calif. -- Obagi Medical Products, Inc. (NASDAQ: OMPI), the leader in skin health, today announced the launch of a new acne therapy - CLENZIderm M.D.[TM] Acne Therapeutic System. The new physician dispensed acne system boasts an advanced, patent-pending Soluzyl Technology[TM] that liquefies Benzoyl Peroxide (BPO) on contact, resulting in greater follicular penetration and rapid lesion reduction.

"We are very excited to bring novel and efficacious technology to the field of acne treatment, a market valued at $1.3 billion," said Steven Carlson, President of Obagi Medial Products. "Studies indicate that no other single acne treatment or combination therapy is proven to work on all three causes of acne, including excess oil, acne-causing bacteria and clogged pores. We believe this scientific breakthrough represents a significant treatment advance in the acne category and establishes a new market opportunity for Obagi Medical Products."

The CLENZIderm M.D. Acne Therapeutic System uses a combination of salicylic acid and a new, prescription strength gel form of liquefied BPO that allows for more rapid and deeper penetration into the follicle to control acne quickly. Most BPO's are formulated with insoluble micro-crystals, which remain largely on the surface of the skin, limiting their ability to penetrate beyond outer skin layers. Obagi's patented Soluzyl Technology liquefies the BPO, resulting in greater follicular penetration within the skin.

Clinical studies show that consistent use of CLENZIderm M.D. Acne Therapeutic System results in a greater reduction of follicular bacteria associated with acne in as early as eight hours and demonstrates both a 52% reduction in inflammatory lesions and a 34% reduction in non-inflammatory lesions in two weeks. Clinical Studies of the CLENZIderm M.D.[TM] Acne Therapeutic System have also demonstrated 80% patient satisfaction by improving the appearance of acne through the rapid clearing of lesions.

CLENZIderm M.D. Acne Therapeutic System is an easy-to-use, highly effective acne system which addresses the compliance challenge associated with achieving superior patient results. Each step in the CLENZIderm M.D. Acne Therapeutic System is designed to complement one another. The Daily Care Foaming Cleanser is used to first remove excess sebum from the skin. The Pore Therapy acts as an exfoliator and removes dead skin cells, priming the skin for the application of the BPO. Lastly, the Serum Gel, containing the Soluzyl Technology and BPO, accelerates follicular penetration by delivering medication deep into the pores.

CLENZIderm M.D. Acne Therapeutic System will be available in dermatologists', plastic surgeons', and skin-care oriented physicians' offices nationwide beginning February 2007.

About Obagi Medical Products, Inc.

Obagi, a leader in the physician-dispensed skin care channel, develops and commercializes skin health products for the dermatology, plastic surgery, and related Aesthetic markets. Using its Penetrating Therapeutics[TM] technologies, Obagi's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin such as chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi launched its first skincare system, Obagi Nu-Derm, in 1988; and in 2004 launched the first and only prescription strength Vitamin C and hydroquinone system, Obagi-C Rx. Obagi System products are only available through physicians. Visit www.obagi.com for information.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to, the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances and the possibility that our products may cause undesirable side effects. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Registration Statement on Form S-1. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.